Private Wealth Asset Management LLC increased its holdings in Merck & Co., Inc. (NYSE:MRK – Free Report) by 285.9% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 85,114 shares of the company’s stock after buying an additional 63,059 shares during the period. Merck & Co., Inc. accounts for 0.7% of Private Wealth Asset Management LLC’s investment portfolio, making the stock its 28th biggest position. Private Wealth Asset Management LLC’s holdings in Merck & Co., Inc. were worth $12,489,000 as of its most recent SEC filing.
Several other institutional investors and hedge funds also recently bought and sold shares of MRK. Round Rock Advisors LLC boosted its holdings in shares of Merck & Co., Inc. by 0.7% in the second quarter. Round Rock Advisors LLC now owns 9,901 shares of the company’s stock worth $1,272,000 after acquiring an additional 66 shares during the period. Cypress Wealth Services LLC grew its position in shares of Merck & Co., Inc. by 0.5% in the third quarter. Cypress Wealth Services LLC now owns 13,807 shares of the company’s stock valued at $1,960,000 after purchasing an additional 69 shares in the last quarter. Code Waechter LLC grew its position in shares of Merck & Co., Inc. by 3.4% in the third quarter. Code Waechter LLC now owns 2,179 shares of the company’s stock valued at $317,000 after purchasing an additional 71 shares in the last quarter. Quest 10 Wealth Builders Inc. raised its stake in shares of Merck & Co., Inc. by 12.2% during the 3rd quarter. Quest 10 Wealth Builders Inc. now owns 699 shares of the company’s stock valued at $102,000 after purchasing an additional 76 shares during the period. Finally, Cascade Financial Partners LLC raised its stake in shares of Merck & Co., Inc. by 0.5% during the 2nd quarter. Cascade Financial Partners LLC now owns 14,746 shares of the company’s stock valued at $1,895,000 after purchasing an additional 80 shares during the period. 76.07% of the stock is owned by institutional investors.
Merck & Co., Inc. Stock Performance
Shares of Merck & Co., Inc. stock opened at $132.74 on Friday. The company has a market capitalization of $327.24 billion, a PE ratio of 136.85, a P/E/G ratio of 6.32 and a beta of 0.13. The company has a 50-day simple moving average of $145.49 and a two-hundred day simple moving average of $129.20. Merck & Co., Inc. has a one year low of $93.90 and a one year high of $156.92. The company has a debt-to-equity ratio of 1.11, a quick ratio of 1.14 and a current ratio of 1.35.
Merck & Co., Inc. (NYSE:MRK – Get Free Report) last released its quarterly earnings results on Thursday, October 29th. The company reported $2.49 earnings per share for the quarter, beating analysts’ consensus estimates of $2.09 by $0.40. Merck & Co., Inc. had a net margin of 3.64% and a return on equity of 16.73%. The business had revenue of $18.09 billion for the quarter, compared to analysts’ expectations of $17.33 billion. During the same period last year, the business earned $2.58 EPS. The company’s revenue was up 4.7% compared to the same quarter last year. Research analysts expect that Merck & Co., Inc. will post 2.82 EPS for the current fiscal year.
Merck & Co., Inc. Increases Dividend
The firm also recently announced a quarterly dividend, which will be paid on Friday, January 8th. Investors of record on Tuesday, December 15th will be paid a dividend of $0.88 per share. This is a positive change from Merck & Co., Inc.’s previous quarterly dividend of $0.85. The ex-dividend date is Tuesday, December 15th. This represents a $3.52 annualized dividend and a yield of 2.7%. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 350.52%.
Insiders Place Their Bets
In other Merck & Co., Inc. news, EVP Richard Deluca sold 58,185 shares of the stock in a transaction dated Thursday, November 12th. The stock was sold at an average price of $148.01, for a total value of $8,611,961.85. Following the completion of the sale, the executive vice president directly owned 112,955 shares in the company, valued at approximately $16,718,469.55. This trade represents a 34.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 0.17% of the stock is currently owned by company insiders.
Wall Street Analyst Weigh In
A number of brokerages recently issued reports on MRK. Wolfe Research increased their price objective on Merck & Co., Inc. from $155.00 to $180.00 and gave the stock an “outperform” rating in a report on Tuesday, August 25th. Wall Street Zen raised Merck & Co., Inc. from a “hold” rating to a “strong-buy” rating in a report on Saturday, November 7th. Wells Fargo & Company upped their price target on Merck & Co., Inc. from $150.00 to $170.00 and gave the company an “overweight” rating in a research report on Friday, September 4th. The Goldman Sachs Group upped their price target on Merck & Co., Inc. from $140.00 to $160.00 and gave the company a “buy” rating in a research report on Friday, August 21st. Finally, Barclays increased their price target on shares of Merck & Co., Inc. from $150.00 to $180.00 and gave the stock an “overweight” rating in a report on Monday, October 26th. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and twelve have issued a Hold rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $155.74.
Check Out Our Latest Analysis on Merck & Co., Inc.
Merck & Co., Inc. News Roundup
Here’s some of the latest news about MRK:
- Positive Sentiment: A German court overturned a preliminary injunction that had barred Merck from offering its subcutaneous Keytruda formulation in Germany. This removes an immediate obstacle to distribution, though Halozyme says it will pursue a separate patent-infringement lawsuit seeking permanent relief. Article: Halozyme slips as German court overturns injunction against Merck
- Positive Sentiment: Merck and AI drug-discovery company Isomorphic Labs will collaborate to identify small-molecule candidates for an oncology target. The partnership could support future pipeline development, although it is an early-stage research effort. Article: Merck and Isomorphic Labs Enter Strategic Research Collaboration
- Positive Sentiment: Merck increased its quarterly dividend 3.5% to $0.88 per share, supporting its income appeal. Article: Merck dividend announcement
About Merck & Co., Inc.
Merck & Co., Inc. is a global pharmaceutical company that develops and markets prescription medicines, vaccines, biologic therapies and animal-health products. The company’s research and commercial activities span areas including oncology, infectious diseases, vaccines, cardiovascular disease and immunology. Its products include the cancer medicine Keytruda and the Gardasil vaccine. Founded in the United States in 1891, Merck & Co. became an independent company in 1917. It is headquartered in Rahway, New Jersey, and operates internationally.
See Also
- Five stocks we like better than Merck & Co., Inc.
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK – Free Report).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.
